Exosomes derived from 5-fluorouracil-resistant colon cancer cells are enriched in GDF15 and can promote angiogenesis
Xixi Zheng, Nina Ma, Xingyu Wang, Jiexuan Hu, Xiao Ma, Jingting Wang, Bangwei Cao · Journal of Cancer · 2020
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2020
Abstract
Background: Angiogenesis is important for tumor proliferation and distant metastasis.However, the role of drug-resistant tumor cells in angiogenesis remains largely unknown.Current anti-angiogenic strategies also have limitations and it would be useful to develop novel targets and treatment strategies.Methods: Differential ultracentrifugation was used to isolate conditioned medium-derived exosomes from 5-flurouracil (5-FU)-sensitive or -resistant colon cancer cells.Exosome endocytosis into human umbilical vein endothelial cells was observed via immunofluorescence.Differentially expressed proteins in the exosomes were confirmed via qRT-PCR and Western blotting.The angiogenic capacity of endothelial cells was evaluated using cell function assays and a rat model of abdominal aortic neovascularization.The underlying mechanisms were verified using qRT-PCR and Western blotting assays.Immunohistochemistry was used to evaluate in vivo angiogenesis.
Results:We observed that the conditioned medium and exosomes from 5-FU-resistant colon cancer cells could promote angiogenesis.Exosomal growth/differentiation factor 15 (GDF15) was a potent inducer of this angiogenesis in vitro by inhibiting the Smad signaling pathway, thus increasing periostin (POSTN) levels.Moreover, 5-FU-resistant colon cancer cells showed high microvascular density in vivo.TGF-β1, an activator of the Smad signaling pathway, could partly eliminate those effects.Conclusions: Our study reveals the molecular regulation of angiogenesis in 5-FU-resistant colon cancer and suggests that the GDF15-POSTN axis may be a novel target for anti-angiogenic therapies in colon cancer.
Open the resolved locator · 10.7150/jca.49224
Metadata licence: OpenAlex metadata (CC0)